BioNTech reported strong progress in Q3 2025, showcasing significant advancements in its oncology pipeline and maintaining robust financial health, with a cash position of over EUR 16 billion.

• Continued progress on Pumitamig's global registrational trials in lung cancer, with a Phase III breast cancer trial projected to initiate by year-end.
• Successfully presented promising Phase II trial updates for BNT111 and Autogene cevumeran, reinforcing the potential of mRNA cancer immunotherapies in adjuvant settings.
• Launched a variant-adapted COVID-19 vaccine, augmenting the company’s product portfolio while supporting ongoing oncology transition efforts.
• Significant advancements in AI-driven therapeutic development were showcased during the company's second AI Day, underlining BioNTech's commitment to innovation.
• Financially, the company remains strong, with total cash and equivalents exceeding EUR 16 billion, ensuring flexibility for future investments.